NIKKEI 225
27,720.56 -165.31 (-0.59%) HANG SENG
19,469.46 +28.28 (+0.15%) CRUDE OIL
74.26 +0.01 (+0.01%) GOLD FUTURES
1,782.70 +0.30 (+0.02%) DOW
33,596.34 -350.76 (-1.03%) BTC-GBP
14,042.79 -41.27 (-0.29%)
Equillium, Inc. (0A4D.L)
| Previous close | 1.6680 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 1.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4650 |
| Earnings date | 08 Nov 2022 - 14 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
LA JOLLA, Calif., December 06, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, and Ono Pharmaceutical Co., Ltd. ("Ono"), today announced an option and asset purchase agreement through which Ono gains the exclusive option to purchase Equillium’s rights to itolizumab, a first-in-class monoclonal antibody targeting CD6. These rights include all therapeutic indications and the r
- Business Wire
Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates
LA JOLLA, Calif., November 14, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the third quarter 2022 and provided an update on its clinical development programs.
- Business Wire
Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022
LA JOLLA, Calif., November 14, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that a poster presentation was given over the weekend at ACR Convergence, the annual meeting of the American College of Rheumatology. The presentation highlighted that levels of urinary soluble ALCAM (sALCAM) could be a potential biomarker of disease se
